E. Schülter

发表

Comparison of Classifier Fusion Methods for Predicting Response to Anti HIV-1 Therapy

Thomas Lengauer, E. Aharoni, R. Kaiser, 2008, PloS one.

Prediction of response to antiretroviral therapy by human experts and by the EuResist data‐driven expert system (the EVE study)

Thomas Lengauer, A. Wensing, R. Kaiser, 2010, HIV medicine.

Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database.

Thomas Lengauer, R. Shafer, N. Beerenwinkel, 2009, The Journal of infectious diseases.

Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models

R. Kaiser, A. Altmann, A. Vandamme, 2010, PloS one.

Predicting Response to Antiretroviral Treatment by Machine Learning: The EuResist Project

Thomas Lengauer, R. Kaiser, A. Altmann, 2012, Intervirology.

Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment

Giovanni Ulivi, Michal Rosen-Zvi, Anne-Mieke Vandamme, 2008, Antiviral therapy.

EuResist: exploration of multiple modeling techniques for prediction of response to treatment

Giovanni Ulivi, Thomas Lengauer, Yardena Peres, 2007 .

Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype

Thomas Lengauer, Yardena Peres, Rolf Kaiser, 2008, Antiviral therapy.

The EuResist Approach for Predicting Response to Anti HIV-1 Therapy

Joachim Büch, Thomas Lengauer, Yardena Peres, 2008 .

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.

A. Wensing, H. Günthard, P. Reiss, 2016, The Journal of antimicrobial chemotherapy.

Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort

R. Paredes, A. Vandamme, P. Sloot, 2013, BMC Infectious Diseases.

Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey

Thomas Lengauer, R. Kaiser, A. Vandamme, 2019, PloS one.

The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes

H. Walter, R. Kaiser, M. Bickel, 2011, Medical Microbiology and Immunology.

Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors

R. Kaiser, L. Brakier-Gingras, E. Schülter, 2012, Medical Microbiology and Immunology.

Endogenous or exogenous spreading of HIV-1 in Nordrhein-Westfalen, Germany, investigated by phylodynamic analysis of the RESINA Study cohort

Thomas Lengauer, R. Kaiser, E. Schülter, 2012, Medical Microbiology and Immunology.

HIV prevalence and route of transmission in Turkish immigrants living in North-Rhine Westphalia, Germany

Thomas Lengauer, R. Kaiser, J. Rockstroh, 2011, Medical Microbiology and Immunology.

Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries.

S. Sarafianos, E. Arnold, A. Sönnerborg, 2016, The Journal of antimicrobial chemotherapy.

Estimating Trends in the Proportion of Transmitted and Acquired HIV Drug Resistance in a Long Term Observational Cohort in Germany

H. Stellbrink, E. Schülter, B. Jensen, 2014, PloS one.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir

A. De Luca, M. Zazzi, B. Clotet, 2012, Antimicrobial Agents and Chemotherapy.

Efficacy of Antiretroviral Therapy Switch in HIV-Infected Patients: A 10-Year Analysis of the EuResist Cohort

Yardena Peres, Rolf Kaiser, Michal Rosen-Zvi, 2012, Intervirology.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Antiretroviral Therapy Including Tenofovir HIV-1 Patients Treated with Combination of Reverse Transcriptase Mutation K65R in HIV-1 Subtype Is an Independent Predictor

B. Clotet, Z. Grossman, J. Snoeck, 2013 .

Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates.

R. Kaiser, M. Däumer, L. Brakier-Gingras, 2010, The Journal of antimicrobial chemotherapy.

Arevir: A Secure Platform for Designing Personalized Antiretroviral Therapies Against HIV

Joachim Büch, Thomas Lengauer, Joachim Selbig, 2006, DILS.

Transmission of Human Immunodeficiency Virus I Drug Resistance - a Case Report. What are the Clinical Implications?

R. Kaiser, E. Schülter, J. Rockstroh, 2010, European journal of medical research.

Proviral DNA as a Target for HIV-1 Resistance Analysis

Thomas Lengauer, R. Kaiser, E. Schülter, 2015, Intervirology.

Selecting anti-HIV therapies based on a variety of genomic and clinical factors

Thomas Lengauer, Yardena Peres, Michal Rosen-Zvi, 2008, ISMB.

Evolution of raltegravir resistance during therapy.

R. Kaiser, A. Altmann, M. Däumer, 2009, The Journal of antimicrobial chemotherapy.

Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients

M. Madhusudhan, R. Kaiser, E. Schülter, 2014, AIDS.

Correction: Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models

Rolf Kaiser, Michal Rosen-Zvi, Anne-Mieke Vandamme, 2011, PLoS ONE.

The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V

R. Kaiser, E. Schülter, H. Pfister, 2010, AIDS.

Prediction of response to antiretroviral therapy by human experts and by the EuResist data‐driven expert system (the EVE study)

Thomas Lengauer, A. Wensing, R. Kaiser, 2010, HIV medicine.